Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Iavarone

Showing results (111-120 of 145) with videos related to

Pageof 15
Sort By:
Gut|August 22, 2014
A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deteriorationLindsay Y King, Claudia Canasto-Chibuque, Kara B Johnson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 17, 2026
Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data From the LOR-HCC (Lombardy Real-World HCC Group)Andrea Casadei-Gardini, Lorenzo Canova, Federica Tosi, et al.
Cancer Medicine|February 22, 2023
Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantationKyunghye Bang, Andrea Casadei-Gardini, Changhoon Yoo, et al.
Hepatology (Baltimore, Md.)|February 26, 2026
Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world studyFrancesco Tovoli, Massimo Iavarone, Giuseppe Cabibbo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 22, 2025
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus BevacizumabLeonardo Stella, Giuseppe Cabibbo, Ciro Celsa, et al.
Liver Cancer|June 26, 2025
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-BevacizumabBernardo Stefanini, Fabio Piscaglia, Fabio Marra, et al.
Journal of Hepatology|May 23, 2024
Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosisSimone Di Cola, Gennaro D'Amico, Paolo Caraceni, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 1, 2019
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantationMassimo Iavarone, Federica Invernizzi, Carolin Czauderna, et al.
Scientific Reports|November 23, 2025
Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus BevacizumabAndrea Dalbeni, Filippo Cattazzo, Marco Vicardi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 12, 2025
Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on ImmunotherapyMarta Fortuny, Leonardo G da Fonseca, Manon Allaire, et al.
Pageof 15

Showing results (111-120 of 145) with videos related to

Sort By:
Pageof 15
Gut|August 22, 2014
A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deteriorationLindsay Y King, Claudia Canasto-Chibuque, Kara B Johnson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 17, 2026
Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data From the LOR-HCC (Lombardy Real-World HCC Group)Andrea Casadei-Gardini, Lorenzo Canova, Federica Tosi, et al.
Cancer Medicine|February 22, 2023
Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantationKyunghye Bang, Andrea Casadei-Gardini, Changhoon Yoo, et al.
Hepatology (Baltimore, Md.)|February 26, 2026
Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world studyFrancesco Tovoli, Massimo Iavarone, Giuseppe Cabibbo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 22, 2025
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus BevacizumabLeonardo Stella, Giuseppe Cabibbo, Ciro Celsa, et al.
Liver Cancer|June 26, 2025
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-BevacizumabBernardo Stefanini, Fabio Piscaglia, Fabio Marra, et al.
Journal of Hepatology|May 23, 2024
Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosisSimone Di Cola, Gennaro D'Amico, Paolo Caraceni, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 1, 2019
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantationMassimo Iavarone, Federica Invernizzi, Carolin Czauderna, et al.
Scientific Reports|November 23, 2025
Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus BevacizumabAndrea Dalbeni, Filippo Cattazzo, Marco Vicardi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 12, 2025
Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on ImmunotherapyMarta Fortuny, Leonardo G da Fonseca, Manon Allaire, et al.
Pageof 15